WO2006022187A1 - コエンザイムq10含有組成物 - Google Patents
コエンザイムq10含有組成物 Download PDFInfo
- Publication number
- WO2006022187A1 WO2006022187A1 PCT/JP2005/015071 JP2005015071W WO2006022187A1 WO 2006022187 A1 WO2006022187 A1 WO 2006022187A1 JP 2005015071 W JP2005015071 W JP 2005015071W WO 2006022187 A1 WO2006022187 A1 WO 2006022187A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coenzyme
- composition
- water
- mass
- glycerin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to an aqueous liquid containing coenzyme Q containing a water-soluble substance and a polyhydric alcohol.
- Coenzyme Q obtained by dispersing and emulsifying in the body
- composition obtained by dispersing and emulsifying Coenzyme Q in an aqueous liquid containing octenyl succinic acid starch, a water-soluble substance such as dextrin, and glycerin as a polyhydric alcohol.
- the composition can contain a high content of Coenzyme Q, and is stable.
- Coenzyme Q is present in higher animals known as ubidecarenone or coenzyme Q
- Coenzyme Q has high physiological activity and is in vivo.
- Coenzyme Q is a lipophilic solid having a low melting point and is hardly soluble in water. others
- No. 10 is unstable and has a problem that it is decomposed by light or the like to produce hydroquinone, ubichromenol or the like.
- Coenzyme Q is an aqueous emulsion using a fatty acid ester as an emulsifier.
- fat-soluble substances such as Coenzyme Q can be mixed with glycerin fatty acid ester, sucrose fatty acid.
- An emulsion composition containing Coenzyme Q is produced using an emulsifier such as a fatty acid ester.
- JP-A-2003-238396 discloses water-soluble polymers such as starch, dextrin and gum arabic as emulsifiers, but emulsified compositions using these water-soluble polymers instead of synthetic emulsifiers. Contains Coenzyme Q, not manufactured and stable in this way
- emulsified powder that is emulsified by adding processed starch, sugars and water to a fat-soluble substance, and then drying.
- An emulsion powder product containing about 52% of tocopherol acetate is disclosed (Japanese Patent Laid-Open No. 11-196785). However, this method was applied to Coenzyme Q.
- the resulting composition is insufficient in terms of emulsion stability.
- Coenzyme Q can be contained at a high content, and the stability and bioavailability of Coenzyme Q can be increased.
- An object of the present invention is to use a high content of coenzyme Q without using a synthetic emulsifier such as glycerin fatty acid ester, polyglycerin fatty acid ester, organic acid monoglyceride, propylene glycol fatty acid ester, sorbitan fatty acid ester, and sucrose fatty acid ester.
- a synthetic emulsifier such as glycerin fatty acid ester, polyglycerin fatty acid ester, organic acid monoglyceride, propylene glycol fatty acid ester, sorbitan fatty acid ester, and sucrose fatty acid ester.
- zyme Q-containing composition can be produced.
- otate as a water-soluble substance
- the present invention involves dispersing and emulsifying Coenzyme Q in an aqueous liquid containing a specific amount of water-soluble substance and glycerin, which also becomes starch and dextrin starch.
- the present invention relates to the resulting Coenzyme Q-containing liquid composition.
- This Coenzyme Q-containing liquid group
- a carrier can be used as necessary.
- the Coenzyme Q-containing composition of the present invention has a high Coenzyme Q content.
- Coenzyme Q-containing composition of the present invention It is extremely biologic that it can absorb Coenzyme Q even when taken on an empty stomach. It is a highly available composition. For this reason, the Coenzyme Q-containing composition of the present invention
- the Coenzyme Q-containing liquid composition of the present invention comprises octenyl succinic acid starch and dextst.
- the Coenzyme Q-containing liquid composition is obtained.
- Coenzyme Q containing solid composition when dried 10 liquid composition is Coenzyme Q 3-80% by weight, glycerin
- the average particle size of dispersed particles is 3
- the average particle size at the time of water dispersion is stably maintained when the liquid composition is stored for a long time.
- the content of Coenzyme Q in the composition of the present invention depends on the desired intake amount and the form of the composition.
- the daily intake of Coenzyme Q is the age
- the strength varies depending on body weight and health condition. Usually, it is 5 to 600 mgZ days, preferably 10 to 3 OOmgZ days for adults.
- Kokonzym Q is dispersed and emulsified as uniform and fine particles to reduce the emulsion.
- Water-soluble substances include gum arabic, various starches, gelatin, xanthan gum, casein, carmellose sodium (CMC sodium), guar gum, pullulan, carrageenan, polybulur pyrrolidone (PVP), polybulal alcohol (PVA), carboxibi
- PVP polybulur pyrrolidone
- PVA polybulal alcohol
- the combination of octenyl succinate starch and dextrin is optimal for obtaining a stable emulsion containing 10 particles.
- raw material powder of otaturosuccinic acid powder examples include tapio starch, potato starch, corn starch, starch corn starch, rice starch, and wheat starch.
- dextrin examples include the aforementioned starch hydrolyzate and maltodextrin.
- a water-soluble substance which also includes octenyl succinate starch and dextrin.
- composition depends on the form of the composition (liquid or solid), the content of Coenzyme Q, etc. For liquid compositions, based on the weight of the composition.
- the blending ratio of octenyl succinate starch and dextrin in the water-soluble substance is in the range of 5 to 95:95 to 5, preferably in the range of 25 to 80:75 to 20, as a mass ratio. .
- Octo-Lucuccinic acid starch and dextrin blending ratio S The effect of the combination becomes low, and as a result, a uniform, fine, and stable emulsion, that is, the intended Coenzyme Q-containing composition cannot be obtained.
- polyhydric alcohol examples include glycerin, propylene glycol, polyethylene glycol, sugar alcohols (for example, sorbitol, erythritol, mannitol, xylitol, etc.), sugars such as glucose, fructose, sucrose, maltose, In order to obtain a stable emulsion containing uniform and fine coenzyme Q, the most suitable one is glycerin.
- a sufficient effect can be obtained by using food-grade glycerin alone with pharmaceutical-use glycerin.
- the content of glycerin varies depending on the form of the composition (liquid or solid), the content of Coenzyme Q, etc. In the case of a liquid composition, it is based on the weight of the composition.
- the range is 0.01 to 10% by mass, and preferably 0.5 to 5% by mass. Moreover, when it is a solid composition, it is the range of 0.01-25 mass%, Preferably it is 0.1-10 mass%.
- succinate starch and dextrin are used, other water-soluble substances such as gum arabic may be added as long as the effects thereof are not hindered.
- Coenzyme Q is treated with water.
- organic acids can be added to the aqueous liquid.
- organic acids include, for example, succinic acid, succinic acid, fumaric acid, lactic acid, darconic acid, malic acid, tartaric acid and salts thereof, preferably citrate, malic acid, tartaric acid or salts thereof or mixtures thereof.
- organic acid salt include a sodium salt, a potassium salt, a magnesium salt, and a strong salt.
- the amount of organic acid added varies depending on the type of organic acid. Generally, it is in the range of 0.01 to 30% by mass, preferably 0 based on the mass of the composition. 05 ⁇ 15% by mass.
- the liquid composition when organic acid is added is Coenzyme Q 1-50 quality.
- % By weight, 0.01 to 10% by mass of glycerin, 4 to 30% by mass of water-soluble substance, 0.01 to 10% by mass of organic acid and 40 to 94% by mass of water.
- the solid composition with organic acid added is Coenzyme Q 3-80% by mass, glycerin 0.01-25% by mass, water-soluble material
- composition containing the organic acid can be diluted or concentrated as it is and used as a food material, a pharmaceutical material, a cosmetic material, or a feed additive.
- a fine and uniform emulsion can be formed by finely dispersing and emulsifying to a desired average particle size using a zener. These steps are preferably carried out at a temperature above the melting point of Coenzyme Q10, for example about 45-90 ° C, preferably 50-70 ° C.
- Coenzyme Q10 drug substance is directly added to and dispersed in an aqueous solution that has been pre-warmed (about 45 to 90 ° C, preferably 50 to 70 ° C), dissolved in the solution, and then emulsified. It's good. This method is preferable because the workability is improved and the loss of raw materials can be suppressed.
- Coenzyme Q is mixed with oil or edible oil.
- An organic acid may be added.
- the specific water-soluble substance used in the present invention stably retains fine emulsified particles of Coenzyme Q from the production of the composition of the present invention to the intake and absorption thereof.
- any dry / solid means commonly used in the manufacture of pharmaceutical preparations can be used.
- a fluidized bed fluidized by a heated updraft as necessary.
- the liquid composition of the present invention is added to the fluidized bed stirred with a stirring blade or the like by dropping or spraying, etc. Examples thereof include freeze-drying.
- the liquid composition of the present invention can be solidified, for example, powdered, by subjecting it to drying / solidifying means such as spray drying, spray cooling, freeze drying, etc., without adding a carrier.
- drying / solidifying means such as spray drying, spray cooling, freeze drying, etc.
- a good solid composition capable of forming a fine and stable aqueous composition when dissolved or dispersed in an aqueous liquid can be obtained. If necessary, it may be adsorbed or supported on a carrier and solidified, for example, powdered. In this case, any ingestible carrier capable of adsorbing or supporting the liquid composition can be used.
- the functional properties of the resulting solid preparation can be changed by appropriately selecting the carrier.
- the water solubility of the product can be further increased.
- lactose, sorbitol and Z or crystalline cellulose are used, a directly compressible composition having plastic deformation ability or a food containing the same can be obtained. Effervescent tablets and the like can also be appropriately prepared.
- the amount of the carrier in the solid composition is determined as Coenzyme Q, glycerin, a water-soluble substance and, if necessary,
- the range is 10 to 800 parts by mass.
- vitamins or the like can be blended as appropriate.
- Water-soluble vitamins include vitamin B group and vitamin C.
- the vitamin B group includes vitamin B derivatives, vitamin B,
- Vitamin B derivatives include thiamine or its
- vitamin B such as salt, thiamine disulfide, fursultiamine or its salt, dicetiamine, bisbuthiamine, bisbenchamine, benfotiamine, thiamine monophosphate disulnoleide, chicotiamine, octothiamine, prosultiamine
- fat-soluble vitamins include vitamin E, vitamin D or derivatives thereof, vitamins, vitamins, vitamin ⁇ , and ⁇ -carotene.
- the amount of vitamins to be blended is appropriately determined according to the type, the form of the final product to be produced, and the amount of intake that should be desired. Specifically, it is in the range of 0.001 to 30% by mass, preferably 0.01 to 10% by mass, for example, about 1% by mass. In the case of liquids and beverages, the range is 0.0001 to 10% by mass, preferably about 0.001 to 3% by mass.
- composition of the present invention minerals such as calcium, potassium, iron, zinc and yeast or their contents, L-cartine, creatine, a-lipoic acid , Glutathione, Glucuronic acid, Taurine, Collagen, Soy isoflavone, Lecithin, Peptide, Amino acids, ⁇ -Aminobutyric acid, Diacylglycerol, DHA, EPA, Medium chain fatty acid triglyceride, Edible oils and fats, Kabusaicin, Chondroitin sulfate, Agaritas Extract, carrot extract, garlic extract, glucan, green juice, royal jelly, propolis, octacosanol, NADH, D-lipose, ceramide, hyaluronic acid, flavanjenol, pycnogenol, ma force, chitosan, garcinia extract, chondroitin, darcosamine, Caseinu Naturiu
- Other ingredients include herbs such as yew leaves extract, grape seed extract, and parelian extract, as well as herbal medicines such as ginseng, such as Tochu tea, oolong tea, green tea, black tea, , Tomgi tea, etc. may be blended.
- herbs such as yew leaves extract, grape seed extract, and parelian extract
- herbal medicines such as ginseng, such as Tochu tea, oolong tea, green tea, black tea, , Tomgi tea, etc. may be blended.
- compositions of the present invention tablets, tablet confectionery, chewable tablets, powders, capsules, granules, liquid foods such as tube enteral nutrition, health foods such as drinks Also Is a dietary supplement, tea drinks such as green tea, oolong tea and black tea, soft drinks, jelly drinks, sport drinks, milk drinks, carbonated drinks, fruit juice drinks, lactic acid bacteria drinks, fermented milk drinks, powdered drinks, cocoa drinks, purified water, etc.
- the food of the present invention comprises other food materials used in the production thereof, various nutrients, various vitamins, minerals, dietary fiber, various additives such as taste ingredients, sweeteners, acid acids such as organic acids, stabilizers, It can be produced according to a conventional method by blending flavor and the like.
- the dosage form includes tablets, capsules, condyles, powders, syrups, suspensions, ointments, creams, gels, patches, Etc.
- the medicament of the present invention has a dosage form of commonly used excipients, disintegrants, binders, lubricants, surfactants, alcohols, water, water-soluble polymers, sweeteners, corrigents, acidulants and the like. It can be added according to the conventional method.
- the liquid preparation may be dissolved or suspended in water or other appropriate medium when taken. Tablets and granules may be coated by a known method.
- animal feed such as livestock feed or pet food can be produced using the composition of the present invention as feed raw material or material, and can be ingested by animals such as livestock or pets.
- composition of the present invention can be applied to cosmetics such as creams, emulsions, lotions, lipsticks or lip balms as it is or in the same manner as pharmaceuticals.
- the Q-containing composition is easily soluble in water and has excellent taste.
- Example 1 Otaturus succinic acid powdered sodium (Matsuya Igaku Kogyo) 800g, dextrin (Matsutani Igaku Kogyo) 300g and glycerol lOOg are added to purified water 4000g and heated to about 60 ° C. Add 800 g of Kokonzym Q (Nisshin Faluma) and mix, and then add high-pressure homogen
- a finer and uniform emulsion was obtained by passing through a nizer (processing pressure 700 kgZcm 2 , 3 times).
- the particle size of dispersed emulsified particles containing Coenzyme Q in this emulsion is measured by laser.
- the 50% particle size was 0.31 ⁇ m.
- this emulsion was ejected into a hot air stream heated to 180 ° C. to remove water, and an orange powder composition containing 40% by mass of Coenzyme Q was obtained.
- Otaturus succinic acid disintegrated sodium 800g
- dextrin Matsutani Igaku Kogyo
- glycerin 60g and malic acid 40g are added to purified water 4000g and heated to about 60 ° C.
- the mixture was passed through a high-pressure homogenizer (processing pressure 700 kgZcm 2 , 3 times) to obtain a fine and uniform emulsion.
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.41 ⁇ m.
- Otatururic acid sodium powder (Matsuya Chemical Industry) 240g, dextrin (Matsutani Chemical Industry) 120g and glycerin 24g are added to purified water 1200g and heated to about 60 ° C.
- Add 416 g of Coenzyme Q (manufactured by Nisshin Faluma), mix, and then add high-pressure homogenizer.
- a finer and uniform emulsion was obtained by passing through a nizer (processing pressure 700 kgZcm 2 , 3 times).
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- Otaturus succinic acid powdered sodium (Matsutani Chemical Industry) 240g, dextrin (Matsutani Chemical Industry) 80g, gum arabic (Ina Food Industry) 40g and glycerin 24g are added to purified water 1200g and heated to about 60 ° C.
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.48 m.
- Otaturosuccinic acid disintegrated sodium (Matsuya Chemical Co., Ltd.) 240g, dextrin (Matsutani Chemical Industry Co., Ltd.) 104g, glycerin 24g and malic acid 16g are added to purified water 1200g and heated to about 60 ° C.
- Add 416 g of Coenzyme Q (manufactured by Nisshin Faluma) and mix.
- the mixture was passed through a high-pressure homogenizer (processing pressure 700 kgZcm 2 , 3 times) to obtain a fine and uniform emulsion.
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.44 m.
- Example 5 400 g of the emulsion obtained in Example 5 was powdered in a fluidized bed using 2400 g of dextrin (manufactured by Sanwa Starch) as a carrier to obtain an orange-yellow powder to a granular powder composition.
- dextrin manufactured by Sanwa Starch
- Example 5 400 g of the emulsion obtained in Example 5 was powdered in a fluidized bed using 1800 g of dextrin (manufactured by Sanwa Starch) and 600 g of sorbitol (manufactured by Nikken Kasei) as a carrier. A powder-granular powder composition was obtained.
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.33 m.
- this emulsion was ejected into a hot air stream heated to 180 ° C. to remove water, thereby obtaining an orange powder composition (solid preparation).
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.39 m.
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.45 m.
- Otatur Succinic acid disintegrated sodium (Matsutani Chemical Co., Ltd.) I40g, dextrin (Matsutani Chemical (Industry) 200g and lactose (DMV) 140g are added to purified water 1400g and heated to about 60 ° C.
- Coenzyme Q (Nisshin Faluma) (320 g) was added to this and mixed.
- a fine and uniform emulsion was obtained by passing through a homogenizer (processing pressure 700 kgZcm 2 , 3 times).
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.63 m.
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.64 m.
- Sodium otaturuccinate starch (manufactured by Matsutani Chemical Industry Co., Ltd.) 800 g, gum arabic (manufactured by Ina Foods Co., Ltd.) 340 g and glycerin 60 g are added to purified water 4000 g and heated to about 60 ° C. Add 800 g of Coenzyme Q (Nisshin Faluma), mix, and then add high-pressure homogen.
- a fine and uniform emulsion was obtained by passing through a generator (processing pressure 700 kgZcm 2 , 3 times).
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.81 ⁇ m.
- Dex's phosphorus (Matsutani Igaku Kogyo) 690g, lecithin 50g, soybean oil 400g, glycerin 60g, purified water 4000g, heat up to about 60 ° C.
- Coenzyme Q (Nisshin Faar
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.72 m.
- the mixture was further passed through a high-pressure homogenizer (processing pressure 700 kgZcm 2 , 3 times). However, immediately after the treatment, the force that formed the emulsion was separated immediately, and it was impossible to maintain a uniform emulsion.
- Hydroxypropyl starch (manufactured by Nissho Chemical Co., Ltd.) 400 g, dextrin (manufactured by Matsutani Chemical Co., Ltd.) 340 g, sodium caseinate 400 g, and glycerin 60 g are calorie-free in 4000 g of purified water and heated to about 60 ° C. Add 800 g of Coenzyme Q (Nisshin Faluma), mix, and press.
- a fine and uniform emulsion was obtained by passing through a homogenizer (processing pressure 700 kgZcm 2 , 3 times).
- Example 1 The particle size of the dispersed emulsified particles containing Coenzyme Q in this emulsion is shown in Example 1.
- the 50% particle size was 0.75 m.
- the 50% particle size of the emulsified particles is 0.62 / zm (Comparative Example 10) and 0.55 / zm (Comparative Example 11), respectively. And 0.48 m (Comparative Example 12).
- a powder composition containing% was obtained.
- composition of the present invention contains a high content of Coenzyme Q.
- Disperse lg powder compositions of Examples 2, 3 and 5 and Comparative Examples 1 and 2 in 100 ml of water The residual rate of Coenzyme Q in the dispersed liquid was measured.
- Table 2 shows the residual rate% when the glass bottle packaging start time is 100%.
- composition of the present invention contains Coenzyme Q in a high content
- Example 1 100.0 99.9 98.0 97.8 Comparative example 5 100.0 96.8 92.9 89.5 Comparative example 6 100.0 95.8 93.7 87.3 Comparative example 7 100.0 96.1 93.9 89.7 Comparative example 9 100.0 97.9 94.1 87.8 Comparative example 10 100.0 98.1 94.4 88.4 Comparative Example 11 100.0 97.3 94.1 88.7 Comparative Example 12 100.0 96.2 93.8 88.5 From the results in Tables 3 and 4, the results were compared with the Coenzyme Q-containing composition of the present invention (Example 1).
- compositions of Comparative Examples 5, 6, 7, 9, 10, 11, and 12 had an increased average particle size at the time of dispersion that was difficult to disperse in water after long-term storage.
- precipitation does not occur after storage for 4-6 weeks.
- dispersion stability in water after long-term storage there was a problem in dispersion stability in water after long-term storage.
- residual rate of Coenzyme Q begins to decrease for 2 to 4 weeks after long-term storage, and after 6 weeks it becomes less than 90%.
- the capsule was forcibly administered with 100 ml of water without feeding in the morning on the test day.
- Coenzyme Q was measured using HPLC under the following conditions. There is acid in the serum.
- Example 1 AUC (0 ⁇ t) ( ⁇ g / hr / ml) Area under blood concentration one hour curve [0061] As a result of these absorbability tests, the composition of Example 1 was more reliable than the composition of Comparative Example 3 in terms of the plasma concentration of Coenzyme Q, even when administered orally under fasting. High concentration
- L-Carthine L-Tartrate 100g Crystalline cellulose (Asahi Kasei) 260g, Lactose (DM V) 80g, HPC (Nippon Soda) (hydroxypropylcellulose) 10g are mixed and kneaded with 80mL of ethanol. Knead for 5 minutes using the usual method. After kneading, sieve through 10 mesh and dry at 50 ° C in a dryer. After drying, the particles were sized to obtain granules. To this condylar granule, 150 g of the powder composition of Example 2 was added and mixed to produce a granule containing Coenzyme Q.
- a granule containing 120 mg of 10 was obtained.
- Crystalline cellulose made by Asahi Kasei
- lactose made by DMV
- HPC made by Nippon Soda
- hydroxypropylcellulose 18g are mixed and kneaded for 5 minutes in a kneading machine with 130 ml of ethanol by a usual method. After kneading, it is sieved with 16 mesh and dried in a dryer at 50 ° C. After drying, the granules were sized to obtain granules.
- sucrose fatty acid ester Mitsubishi Chemical
- 150 g of the powder composition of Example 2 was added and further mixed to prepare a tableting powder.
- This powder was tableted using a tableting machine to prepare one tablet of 300 mg. This tablet contains 30mg of Coenzyme Q per tablet.
- Example 2 250 g of the powder composition obtained in Example 2, 580 g of crystalline cellulose (manufactured by Asahi Kasei) and 130 g of reduced maltose (manufactured by Niken Ichinari) are mixed, and sucrose fatty acid ester (manufactured by Mitsubishi Igaku) is mixed there. 40 g was added and further mixed to prepare a tableting powder. This powder was tableted using a tableting machine to prepare 500 mg tablets per tablet. This tablet has a Coenzyme Q of 5 per tablet.
- Chenic acid manufactured by Tanabe Seiyaku
- glucose solution manufactured by Nippon Food Processing Industry Co., Ltd.
- 150 g of the powder composition of Example 2 was added and dissolved to obtain a uniform beverage composition containing Coenzyme Q.
- Example 2 225 g of the powder composition of Example 2, 15 g of vitamin B, 30 g of L-carthine L-tartrate, 390 g of crystalline cellulose (manufactured by Asahi Kasei), 230 g of lactose 200M (manufactured by DMV), 10 g of kenic acid (manufactured by Tanabe Seiyaku) Sieve through 16 mesh to obtain powder. Fill this powder into a No. 2 node capsule with about 300 mg per capsule (containing 30 mg of Coenzyme Q per l capsule).
- Example 16 Mix 200g of flour (strong flour) and 4g of dry yeast. In addition, 2.5 g of the powder composition of Example 2, 10 g of sugar, 4 g of salt, 10 g of skim milk, and 15 g of shortening are dissolved in 150 g of water, and the two are mixed well. Next, after fermenting, it was baked in an oven at 150 ° C for about 15 minutes to produce 10 pieces of bread. About 1OOOmg of coenzyme Q was included in each bread. [0070] [Example 16]
- retort rice contains about 30mg of Coenzyme Q per serving.
- Example 2 Disperse 375 mg of the powder composition of Example 2 and 15 g of sodium chloride in 150 g of water, mix well with 300 g of flour (medium flour) and lay down. After this, the dough was stretched and cut at a width of about 5 mm to produce three servings of udon. When this was boiled in boiling water for about 10 minutes, the appearance, taste and texture were good. This udon contains about 50 mg of Coenzyme Q per serving.
- Example 2 15 g of the powder composition of Example 2 and 585 g of powdered organic green juice (Nisshin Faluma) were mixed well, and then about 3 g of stick packaging per serving was obtained. This powdered green juice contained about 30 mg of Coenzyme Q per stick.
- Example 2 1.5 g of the powder composition of Example 2 was dissolved in 1 L of oolong tea to obtain a beverage. Approximately 60 mg of Coenzyme Q was contained per lOOmL.
- the coenzyme Q is contained in a high content, and the stability and bioavailability of coenzyme Q are improved.
- the liquid composition of the present invention is long despite the high content of Coenzyme Q.
- a good emulsified state is maintained even after storage for a period.
- the solubility or dispersibility in an aqueous liquid such as water does not deteriorate, and a fine and stable aqueous composition can be formed by adding to the aqueous liquid. It is suitable.
- These compositions have the characteristic of reliably absorbing Coenzyme Q even on an empty stomach.
- composition of the present invention can be added to and mixed with various forms of foods, beverages, medicines, cosmetics, and feeds, achieving the highest bioavailability of Coenzyme Q.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006531851A JP4842824B2 (ja) | 2004-08-24 | 2005-08-18 | コエンザイムq10含有組成物 |
CA2575758A CA2575758C (en) | 2004-08-24 | 2005-08-18 | Coenzyme q10-containing composition |
EP05772805.7A EP1782803B1 (en) | 2004-08-24 | 2005-08-18 | Coenzyme q10-containing composition |
US11/632,933 US8119113B2 (en) | 2004-08-24 | 2005-08-18 | Coenzyme Q10—containing composition |
US13/348,335 US8357380B2 (en) | 2004-08-24 | 2012-01-11 | Coenzyme Q10-containing composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-243257 | 2004-08-24 | ||
JP2004243257 | 2004-08-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/632,933 A-371-Of-International US8119113B2 (en) | 2004-08-24 | 2005-08-18 | Coenzyme Q10—containing composition |
US13/348,335 Continuation US8357380B2 (en) | 2004-08-24 | 2012-01-11 | Coenzyme Q10-containing composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006022187A1 true WO2006022187A1 (ja) | 2006-03-02 |
Family
ID=35967400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015071 WO2006022187A1 (ja) | 2004-08-24 | 2005-08-18 | コエンザイムq10含有組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8119113B2 (ja) |
EP (1) | EP1782803B1 (ja) |
JP (1) | JP4842824B2 (ja) |
CA (1) | CA2575758C (ja) |
TW (1) | TWI351925B (ja) |
WO (1) | WO2006022187A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006141247A (ja) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | コエンザイムq10を含有する細胞培養用の培地組成物 |
JP2006160730A (ja) * | 2004-11-12 | 2006-06-22 | Taisho Pharmaceut Co Ltd | 低融点薬物含有粉粒体及びその製造方法 |
JP2006182770A (ja) * | 2004-11-30 | 2006-07-13 | Taisho Pharmaceut Co Ltd | 配合成分が安定化された固形製剤 |
WO2007080787A1 (ja) * | 2006-01-12 | 2007-07-19 | Nisshin Pharma Inc. | コエンザイムq10含有水溶性組成物 |
WO2009001787A1 (ja) | 2007-06-22 | 2008-12-31 | Kaneka Corporation | 補酵素q10含有組成物 |
EP2098222A1 (en) * | 2006-10-31 | 2009-09-09 | Kaneka Corporation | Physiologically active substance-containing granular composition and method of producing the same |
JP2009240219A (ja) * | 2008-03-31 | 2009-10-22 | Riken Vitamin Co Ltd | 脂溶性ビタミン含有可溶化組成物 |
JPWO2009001786A1 (ja) * | 2007-06-22 | 2010-08-26 | 株式会社カネカ | 生理活性物質含有組成物 |
CN101288641B (zh) * | 2007-04-19 | 2012-07-11 | 浙江一新制药股份有限公司 | 辅酶q10水分散体及其制备方法 |
JP2013529062A (ja) * | 2010-03-29 | 2013-07-18 | フイルメニツヒ ソシエテ アノニム | 噴霧乾燥した結晶性活性成分 |
WO2014010332A1 (ja) * | 2012-07-13 | 2014-01-16 | 富士フイルム株式会社 | 飲料 |
US8809398B2 (en) | 2007-01-16 | 2014-08-19 | Basf Se | Liquid formulations containing a carotinoid |
WO2016024344A1 (ja) * | 2014-08-13 | 2016-02-18 | 日清ファルマ株式会社 | 家畜類の生産方法および家畜類の成長促進方法 |
JP2016101157A (ja) * | 2014-11-13 | 2016-06-02 | 日清オイリオグループ株式会社 | 粉末油脂、該粉末油脂を含む飲食品、及び該粉末油脂の製造方法 |
JP2018203618A (ja) * | 2017-05-30 | 2018-12-27 | 日清ファルマ株式会社 | コエンザイムq10フィルム製剤 |
JP2019055927A (ja) * | 2017-09-22 | 2019-04-11 | 日清ファルマ株式会社 | コエンザイムq10含有固形組成物 |
WO2019167663A1 (ja) * | 2018-02-28 | 2019-09-06 | ペトロユーロアジア株式会社 | 還元型補酵素q10含有組成物およびその製造方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100047869A (ko) * | 2007-07-19 | 2010-05-10 | 디에스엠 아이피 어셋츠 비.브이. | 친유성 헬스 성분의 정제화가능한 배합물 |
US20110123505A1 (en) * | 2007-08-22 | 2011-05-26 | Kaneka Corporation | Method of producing reduced coenzyme q10 and method of stabilizing the same |
CN102176833B (zh) † | 2008-10-07 | 2018-03-16 | 巴斯夫欧洲公司 | 即用型稳定乳液 |
RU2411027C1 (ru) * | 2009-06-24 | 2011-02-10 | Пация Мераби Георгиевич | Нанодисперсная композиция с коэнзимом q10 и способ ее получения |
US9050357B2 (en) * | 2010-03-08 | 2015-06-09 | Cp Kelco U.S., Inc. | Compositions and methods for producing consumables for patients with dysphagia |
ITUD20110196A1 (it) | 2011-12-02 | 2013-06-03 | Asoltech S R L | Composizione a base di ubidecarenone |
KR101404990B1 (ko) | 2012-05-30 | 2014-06-10 | 고려대학교 산학협력단 | 코엔자임 q10 전분 복합체를 포함하는 기능성 음료 및 이의 제조방법 |
TWI531318B (zh) | 2013-12-20 | 2016-05-01 | 財團法人食品工業發展研究所 | 微乳液預濃縮物和微乳液暨其製備方法 |
WO2016074800A1 (en) * | 2014-11-14 | 2016-05-19 | Asoltech S.R.L. | Composition based on coq10 |
US20190183815A1 (en) * | 2016-08-15 | 2019-06-20 | Corr-Jensen Inc. | TIME RELEASE OF CoQ10 |
TWI623616B (zh) * | 2016-11-30 | 2018-05-11 | 財團法人食品工業發展研究所 | 黑酵母菌、生產β-葡聚糖之培養基與方法、黑酵母菌培養物與含其組成物 |
CN111374965B (zh) * | 2018-12-28 | 2024-01-16 | 上海融澈水性材料有限公司 | 一种稳定性高的水溶性辅酶q10包合物及其制备方法 |
CN113940909B (zh) * | 2021-11-12 | 2023-03-14 | 广州睿森生物科技有限公司 | 一种调节昼夜节律的组合物及其应用 |
CN115487140B (zh) * | 2022-09-26 | 2023-08-29 | 马鞍山丰原制药有限公司 | 一种辅酶q10注射剂及制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6028915A (ja) * | 1983-07-26 | 1985-02-14 | Eisai Co Ltd | ユビデカレノン高含量含有組成物 |
JPH11196785A (ja) * | 1998-01-20 | 1999-07-27 | Eisai Co Ltd | 乳化粉末及びその製造法 |
JP2000325043A (ja) * | 1999-05-17 | 2000-11-28 | Matsutani Chem Ind Ltd | 可溶性イソフラボン組成物及びその製造方法 |
JP2003055203A (ja) * | 2001-08-10 | 2003-02-26 | Nisshin Pharma Inc | ユビキノン含有製剤 |
JP2003520827A (ja) * | 2000-01-27 | 2003-07-08 | ワツカー−ケミー ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 補酵素Q10/γ−シクロデキストリン複合体の製造方法 |
JP2003238396A (ja) * | 2002-02-21 | 2003-08-27 | Nisshin Pharma Inc | コエンザイムq10含有乳化組成物 |
JP2003300870A (ja) * | 2002-02-08 | 2003-10-21 | Kyowa Hai Foods Kk | ユビキノン含有水可溶性組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5951214A (ja) | 1982-09-16 | 1984-03-24 | Taiho Yakuhin Kogyo Kk | バイオアベイラビリテイの高い薬剤の製造方法 |
JP3880265B2 (ja) * | 1998-11-16 | 2007-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性物質の水性液剤 |
US6479058B1 (en) * | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
DE10141258B4 (de) * | 2001-08-23 | 2004-09-23 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitung und ihre Verwendung |
-
2005
- 2005-08-18 JP JP2006531851A patent/JP4842824B2/ja active Active
- 2005-08-18 CA CA2575758A patent/CA2575758C/en not_active Expired - Fee Related
- 2005-08-18 WO PCT/JP2005/015071 patent/WO2006022187A1/ja active Application Filing
- 2005-08-18 EP EP05772805.7A patent/EP1782803B1/en not_active Not-in-force
- 2005-08-18 US US11/632,933 patent/US8119113B2/en not_active Expired - Fee Related
- 2005-08-23 TW TW094128802A patent/TWI351925B/zh not_active IP Right Cessation
-
2012
- 2012-01-11 US US13/348,335 patent/US8357380B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6028915A (ja) * | 1983-07-26 | 1985-02-14 | Eisai Co Ltd | ユビデカレノン高含量含有組成物 |
JPH11196785A (ja) * | 1998-01-20 | 1999-07-27 | Eisai Co Ltd | 乳化粉末及びその製造法 |
JP2000325043A (ja) * | 1999-05-17 | 2000-11-28 | Matsutani Chem Ind Ltd | 可溶性イソフラボン組成物及びその製造方法 |
JP2003520827A (ja) * | 2000-01-27 | 2003-07-08 | ワツカー−ケミー ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 補酵素Q10/γ−シクロデキストリン複合体の製造方法 |
JP2003055203A (ja) * | 2001-08-10 | 2003-02-26 | Nisshin Pharma Inc | ユビキノン含有製剤 |
JP2003300870A (ja) * | 2002-02-08 | 2003-10-21 | Kyowa Hai Foods Kk | ユビキノン含有水可溶性組成物 |
JP2003238396A (ja) * | 2002-02-21 | 2003-08-27 | Nisshin Pharma Inc | コエンザイムq10含有乳化組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1782803A4 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006160730A (ja) * | 2004-11-12 | 2006-06-22 | Taisho Pharmaceut Co Ltd | 低融点薬物含有粉粒体及びその製造方法 |
JP2006141247A (ja) * | 2004-11-17 | 2006-06-08 | Nisshin Pharma Inc | コエンザイムq10を含有する細胞培養用の培地組成物 |
JP2006182770A (ja) * | 2004-11-30 | 2006-07-13 | Taisho Pharmaceut Co Ltd | 配合成分が安定化された固形製剤 |
WO2007080787A1 (ja) * | 2006-01-12 | 2007-07-19 | Nisshin Pharma Inc. | コエンザイムq10含有水溶性組成物 |
EP2098222A4 (en) * | 2006-10-31 | 2012-12-26 | Kaneka Corp | GRANULAR COMPOSITION CONTAINING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND METHOD FOR PRODUCING THE SAME |
EP2098222A1 (en) * | 2006-10-31 | 2009-09-09 | Kaneka Corporation | Physiologically active substance-containing granular composition and method of producing the same |
US8809398B2 (en) | 2007-01-16 | 2014-08-19 | Basf Se | Liquid formulations containing a carotinoid |
CN101288641B (zh) * | 2007-04-19 | 2012-07-11 | 浙江一新制药股份有限公司 | 辅酶q10水分散体及其制备方法 |
JPWO2009001786A1 (ja) * | 2007-06-22 | 2010-08-26 | 株式会社カネカ | 生理活性物質含有組成物 |
JP5343002B2 (ja) * | 2007-06-22 | 2013-11-13 | 株式会社カネカ | 生理活性物質含有組成物 |
WO2009001787A1 (ja) | 2007-06-22 | 2008-12-31 | Kaneka Corporation | 補酵素q10含有組成物 |
JP2009240219A (ja) * | 2008-03-31 | 2009-10-22 | Riken Vitamin Co Ltd | 脂溶性ビタミン含有可溶化組成物 |
JP2013529062A (ja) * | 2010-03-29 | 2013-07-18 | フイルメニツヒ ソシエテ アノニム | 噴霧乾燥した結晶性活性成分 |
WO2014010332A1 (ja) * | 2012-07-13 | 2014-01-16 | 富士フイルム株式会社 | 飲料 |
JP2014030422A (ja) * | 2012-07-13 | 2014-02-20 | Fujifilm Corp | 飲料 |
WO2016024344A1 (ja) * | 2014-08-13 | 2016-02-18 | 日清ファルマ株式会社 | 家畜類の生産方法および家畜類の成長促進方法 |
JPWO2016024344A1 (ja) * | 2014-08-13 | 2017-05-18 | 日清ファルマ株式会社 | 家畜類の生産方法および家畜類の成長促進方法 |
JP2016101157A (ja) * | 2014-11-13 | 2016-06-02 | 日清オイリオグループ株式会社 | 粉末油脂、該粉末油脂を含む飲食品、及び該粉末油脂の製造方法 |
JP2018203618A (ja) * | 2017-05-30 | 2018-12-27 | 日清ファルマ株式会社 | コエンザイムq10フィルム製剤 |
JP2019055927A (ja) * | 2017-09-22 | 2019-04-11 | 日清ファルマ株式会社 | コエンザイムq10含有固形組成物 |
WO2019167663A1 (ja) * | 2018-02-28 | 2019-09-06 | ペトロユーロアジア株式会社 | 還元型補酵素q10含有組成物およびその製造方法 |
JPWO2019167663A1 (ja) * | 2018-02-28 | 2021-02-18 | ペトロユーロアジア株式会社 | 還元型補酵素q10含有組成物およびその製造方法 |
JP7273278B2 (ja) | 2018-02-28 | 2023-05-15 | ペトロユーロアジア株式会社 | 還元型補酵素q10含有組成物およびその製造方法 |
US11911350B2 (en) | 2018-02-28 | 2024-02-27 | Petroeuroasia Co., Ltd. | Reduced coenzyme Q10-containing composition and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
TWI351925B (en) | 2011-11-11 |
US8119113B2 (en) | 2012-02-21 |
JPWO2006022187A1 (ja) | 2008-05-08 |
EP1782803B1 (en) | 2015-06-03 |
CA2575758C (en) | 2012-11-13 |
EP1782803A1 (en) | 2007-05-09 |
US8357380B2 (en) | 2013-01-22 |
TW200616557A (en) | 2006-06-01 |
US20080248013A1 (en) | 2008-10-09 |
EP1782803A4 (en) | 2012-07-18 |
JP4842824B2 (ja) | 2011-12-21 |
US20120107374A1 (en) | 2012-05-03 |
CA2575758A1 (en) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4842824B2 (ja) | コエンザイムq10含有組成物 | |
JP5147239B2 (ja) | コエンザイムq10含有乳化組成物 | |
KR100354310B1 (ko) | 아지스로마이신투여방법 | |
CN101247801B (zh) | 血中酒精浓度上升抑制用组合物 | |
TWI352579B (en) | Compositions containing coenzyme q10 | |
AU8028287A (en) | A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it | |
WO2006030850A1 (ja) | 脂溶性成分の可溶化物の調製方法 | |
JP7084926B2 (ja) | 高カロリー栄養組成物および包装体 | |
KR20090008227A (ko) | 흡습성이 개선된 음식품용 조성물 | |
JP2006320311A (ja) | コエンザイムq10およびミネラル類を含有する食品並びにその製造方法 | |
JP2004242509A (ja) | コエンザイムq10およびアミノ酸類を含有する食品 | |
JPWO2009048120A1 (ja) | アスタキサンチン含有水溶性組成物 | |
WO2007080787A1 (ja) | コエンザイムq10含有水溶性組成物 | |
JP3549019B2 (ja) | コエンザイムq10含有素材 | |
JPWO2019017016A1 (ja) | 包装体 | |
CN100536691C (zh) | 含辅酶q10的组合物 | |
CN112120221A (zh) | 高卡路里营养组合物 | |
JP2007131619A (ja) | コエンザイムq10含有活性組成物 | |
JP2003169630A (ja) | コエンザイムq10を含有する栄養組成物 | |
JP2005097121A (ja) | 運動機能の維持または改善剤 | |
Ikemoto et al. | Coenzyme Q 10—containing composition | |
US20070093554A1 (en) | Agent for improving feeling of cold | |
JP7084925B2 (ja) | 高カロリー栄養組成物および包装体 | |
JP2006137730A (ja) | 抗疲労作用剤又は持久力増強剤、機能性食品又は化粧料 | |
JP2020200046A (ja) | 包装体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11632933 Country of ref document: US Ref document number: 2005772805 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2575758 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006531851 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005772805 Country of ref document: EP |